Literature DB >> 33688358

Network Pharmacology Interpretation of Fuzheng-Jiedu Decoction against Colorectal Cancer.

Hongshuo Shi1, Sisheng Tian2, Hu Tian1.   

Abstract

INTRODUCTION: Traditional Chinese medicine (TCM) believes that the pathogenic factors of colorectal cancer (CRC) are "deficiency, dampness, stasis, and toxin," and Fuzheng-Jiedu Decoction (FJD) can resist these factors. In this study, we want to find out the potential targets and pathways of FJD in the treatment of CRC and also explain from a scientific point of view that FJD multidrug combination can resist "deficiency, dampness, stasis, and toxin."
METHODS: We get the composition of FJD from the TCMSP database and get its potential target. We also get the potential target of colorectal cancer according to the OMIM Database, TTD Database, GeneCards Database, CTD Database, DrugBank Database, and DisGeNET Database. Subsequently, PPI analysis, KEGG pathways analysis, and GO biological processes analysis were carried out for the target of FJD in the therapy of colorectal cancer. In addition, we have also built a relevant network diagram.
RESULTS: In this study, we identified four core compounds of FJD in the therapy of colorectal cancer, including quercetin, kaempferol, beta-sitosterol, and stigmasterol. At the same time, we also obtained 30 core targets, including STAT3, INS, TP53, VEGFA, AKT1, TNF, IL6, JUN, EGF, CASP3, MAPK3, MAPK1, MAPK8, SRC, IGF1, CCND1, ESR1, EGFR, PTEN, MTOR, FOS, PTGS2, CXCL8, HRAS, CDH1, BCL2L1, FN1, MMP9, ERBB2, and JAK2. FJD treatment of colorectal cancer mainly involves 112 KEGG pathways, including FoxO (hsa04068) signaling pathway, PI3K-Akt (hsa04151) signaling pathway, HIF-1 (hsa04066) signaling pathway, T cell receptor (hsa04660) signaling pathway, and ErbB (hsa04012) signaling pathway. At the same time, 330 GO biological processes were summarized, including cell proliferation, cell apoptosis, angiogenesis, inflammation, and immune.
CONCLUSIONS: In this study, we found that FJD can regulate cell proliferation, apoptosis, inflammation and immunity, and angiogenesis through PI3K-Akt signaling pathway to play an anti-CRC effect.
Copyright © 2021 Hongshuo Shi et al.

Entities:  

Year:  2021        PMID: 33688358      PMCID: PMC7914091          DOI: 10.1155/2021/4652492

Source DB:  PubMed          Journal:  Evid Based Complement Alternat Med        ISSN: 1741-427X            Impact factor:   2.629


  70 in total

1.  Restoration of p53 function leads to tumour regression in vivo.

Authors:  Andrea Ventura; David G Kirsch; Margaret E McLaughlin; David A Tuveson; Jan Grimm; Laura Lintault; Jamie Newman; Elizabeth E Reczek; Ralph Weissleder; Tyler Jacks
Journal:  Nature       Date:  2007-01-24       Impact factor: 49.962

Review 2.  Cytokines, IBD, and colitis-associated cancer.

Authors:  Ralph Francescone; Vivianty Hou; Sergei I Grivennikov
Journal:  Inflamm Bowel Dis       Date:  2015-02       Impact factor: 5.325

3.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

4.  Baicalein Inhibits Proliferation Activity of Human Colorectal Cancer Cells HCT116 Through Downregulation of Ezrin.

Authors:  Zhi Chen; Ruizhi Hou; Shuohui Gao; Defeng Song; Ye Feng
Journal:  Cell Physiol Biochem       Date:  2018-09-21

Review 5.  FOXO Signaling Pathways as Therapeutic Targets in Cancer.

Authors:  Mohd Farhan; Haitao Wang; Uma Gaur; Peter J Little; Jiangping Xu; Wenhua Zheng
Journal:  Int J Biol Sci       Date:  2017-07-06       Impact factor: 6.580

6.  The Jun/miR-22/HuR regulatory axis contributes to tumourigenesis in colorectal cancer.

Authors:  Yanqing Liu; Xiaorui Chen; Rongjie Cheng; Fei Yang; Mengchao Yu; Chen Wang; Shufang Cui; Yeting Hong; Hongwei Liang; Minghui Liu; Chihao Zhao; Meng Ding; Wu Sun; Zhijian Liu; Feng Sun; Chenyu Zhang; Zhen Zhou; Xiaohong Jiang; Xi Chen
Journal:  Mol Cancer       Date:  2018-01-19       Impact factor: 27.401

7.  Uncovering the mechanism of Maxing Ganshi Decoction on asthma from a systematic perspective: A network pharmacology study.

Authors:  Wenjie Song; Shenglou Ni; Yanling Fu; Yun Wang
Journal:  Sci Rep       Date:  2018-11-26       Impact factor: 4.379

8.  Utilising network pharmacology to explore the underlying mechanism of Wumei Pill in treating pancreatic neoplasms.

Authors:  Yuxiang Wan; Lin Xu; Zeyu Liu; Ming Yang; Xin Jiang; Qiaoli Zhang; Jinchang Huang
Journal:  BMC Complement Altern Med       Date:  2019-07-04       Impact factor: 3.659

9.  Exploring the Pharmacological Mechanism of the Herb Pair "HuangLian-GanJiang" against Colorectal Cancer Based on Network Pharmacology.

Authors:  Benjiao Gong; Yanlei Kao; Chenglin Zhang; Huishan Zhao; Fudong Sun; Zhaohua Gong
Journal:  Evid Based Complement Alternat Med       Date:  2019-11-29       Impact factor: 2.629

10.  Network pharmacology-based strategy to investigate pharmacological mechanisms of Zuojinwan for treatment of gastritis.

Authors:  Guohua Yu; Wubin Wang; Xu Wang; Meng Xu; Lili Zhang; Lei Ding; Rui Guo; Yuanyuan Shi
Journal:  BMC Complement Altern Med       Date:  2018-11-01       Impact factor: 3.659

View more
  3 in total

1.  Network Pharmacology Analysis on the Mechanism of Huangqi Sijunzi Decoction in Treating Cancer-Related Fatigue.

Authors:  Yixin Cui; Haiming Wang; Decai Wang; Jiwei Mi; Gege Chen; Fagen Li; Yujia Wang; Yin Zhang
Journal:  J Healthc Eng       Date:  2021-11-18       Impact factor: 2.682

2.  Network Pharmacology-Based Investigation on the Mechanism of the JinGuanLan Formula in Treating Acne Vulgaris.

Authors:  Noha Saleh Gholais; Chunrui Shi; Jing Zhang; Bei Liao; Rowida A Albarmaqi; Xiaolong Tang; Leyuan Mi
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-13       Impact factor: 2.650

Review 3.  Inhibition and potential treatment of colorectal cancer by natural compounds via various signaling pathways.

Authors:  Mingchuan Wang; Xianjun Liu; Tong Chen; Xianbin Cheng; Huijie Xiao; Xianglong Meng; Yang Jiang
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.